Market Overview

UPDATE: Credit Suisse Upgrades WuXi PharmaTech to Outperform on Growth Drivers

Related WX
WuXi Congratulates TaiMed Biologics On Receiving Orphan Drug Designation For Ibalizumab From U.S. FDA
Foundation Medicine And WuXi PharmaTech Announce Strategic Collaboration To Offer Best-in-Class Comprehensive Genomic Profiling in China

Credit Suisse raised its rating on WuXi PharmaTech (NYSE: WX) from Neutral to Outperform and increased the price target from $14 to $18.

Credit Suisse noted, "We believe the market under- appreciated WuXi's potential upside from its core growth drivers: (i) Vertically integrated service offerings could benefit more than expected; (ii) Manufacturing business will be scaled-up driven by robust pipelines (four customer drugs move into commercial stage); (iii) Biologics business is on the rise in China, first mover to capture most value (pioneer in setting JV with MNCs such as the AstraZeneca-MedImmune deal)."

WuXi PharmaTech closed at $13.94 on Wednesday.

Latest Ratings for WX

Oct 2013JefferiesMaintainsBuy
Aug 2013JefferiesMaintainsBuy
May 2013JefferiesMaintainsBuy

View More Analyst Ratings for WX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (WX)

Around the Web, We're Loving...

Get Benzinga's Newsletters